Sage Journals: Discover world-class research

Abstract

Purpose

Off-label prescribing of oral oncology agents has been explored in the treatment of soft tissue sarcoma. The time for a prior authorization approval or rejection for an off-label use can be lengthy. The purpose of this study is to capture this burden by comparing the time it takes for patients to receive off-label versus on-label treatment for their soft tissue sarcoma.

Patients and methods

In this retrospective chart review study, patients aged 18 and older who received a new prescription for an oral oncology agent for soft tissue sarcoma from one of three sarcoma providers at Oregon Health & Science University oncology clinics between March 2014 and February 2016 were included. Objectives included comparing the effect of off-label to on-label prescribing of oral oncology agents on time to receipt of medication and patient copays for a 30-day supply of oral chemotherapy agent(s).

Results

The time to receipt of medication (median (IQR)) for the off-label group (N = 26) was 12.5 (3.3 to 30.8) days compared to the on-label group (N = 29), which was 8.0 (4.0 to 15.0) days (p = 0.327). The patient cost was $0.00 ($0.00 to $20.00) for the off-label group (N = 18) compared to $3.00 ($0.00 to $68.80) for the on-label group (N = 18) (p = 0.467).

Conclusions

There were no differences in the time to receipt of medication or patient cost between off-label and on-label prescriptions in soft tissue sarcoma patients. Despite lack of statistical significance, these results are meaningful to patient care and require further study to investigate these findings.

Keywords

Gastrointestinal stromal tumor off-label oral chemotherapy soft tissue sarcoma

Get full access to this article

View all access options for this article.

References

Von Mehren

Benjamin

Bui

et al.

Soft tissue sarcoma, version 2.2016: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2016; 10: 951–960.

National Cancer Institute (NIH). A snapshot off sarcoma, www.cancer.gov/research/progress/snapshots/sarcoma (accessed 11 February 2016).

Clark

Fisher

Judson

et al.

Soft-tissue sarcomas in adults. N Engl J Med 2005; 353: 701–711.

American Cancer Society. Can soft tissue sarcomas be found early?, www.cancer.org/cancer/sarcoma-adultsofttissuecancer/detailedguide/sarcoma-adult-softtissue-cancer-detection (accessed 12 February 2016).

National Cancer Institute (NIH). Drugs approved for soft tissue sarcoma, www.cancer.gov/about-cancer/treatment/drugs/soft-tissue-sarcoma (accessed 12 February 2016).

Collins

Varmus

. A new initiative on precision medicine. N Engl J Med 2015; 372: 793–795.

Borden

Baker

Bell

et al.

Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 2003; 9: 1941–1956.

Reed

Altiok

. Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine. Cancer Control 2011; 18: 188–195.

National Cancer Institute (NIH). Targeted cancer therapies, www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-=sheet (accessed 14 February 2016).

10.

Conti

Bernstein

Villaflor

et al.

Prevalence of off label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol 2013; 31: 1134–1139.

11.

Bradford WB, Turner JL and Williams JW. Off label use of pharmaceuticals: Trends and Drivers. Working Paper.

12.

Niccolai

Roman

Julius

et al.

Potential obstacles in the acquisition of oral anticancer medications. J Oncol Pract 2017; 13: e29–e36.

13.

Academy of Managed Care Pharmacy's Concepts of Managed Care Pharmacy, www.amcp.org/prior_authorization/ (accessed 22 February 2016).

14.

Felder

Lal

Bennett

et al.

Cancer patients' use of pharmaceutical patient assistance programs in the outpatient pharmacy at a large tertiary cancer center. Commun Oncol 2011; 8: 279–286.

15.

American Medical Association. Standardization of prior authorization process for medical services white paper, http://massneuro.org/Resources/Transfer from oldsit/AMA White Paper on Standardizing Prior Authorization (accessed 22 February 2016).

16.

The Prior Authorization (PA) Process for Medications. DVHA Medication PA process (May 2013) State of Vermont Department of Vermont Health Access Pharmacy Benefit Management Program, http://dvha.vermont.gov/for-providers/pa-process-an flow-chart-052813 (2013, accessed 22 February 2016).

17.

Teagarden

Dreitlein

Kourlas

et al.

Influence of pharmacy benefit practices on off label dispensing of drugs in the United States. Clin Pharmacol Ther 2012; 91: 943–945.

18.

Kalis

Pence

Mancini

et al.

Prevalence of off-label use of oral oncolytics at a community cancer center. J Oncol Pract 2015; 11: e139–e143.

19.

Bullard

Eberth

Arrington

et al.

Timeliness of treatment initiation and associated survival following diagnosis of non-small-cell lung cancer in South Carolina. South Med J 2017; 110: 107–113.

20.

Forrest

White

Rubin

et al.

The effect of socioeconomic inequalities in receipt of, and time to, treatment on socioeconomic inequalities in lung cancer survival: an observational, data-linkage study. Lancet 2013. 382(S37).

21.

Mclaughlin

Anderson

Ferketich

et al.

Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 2012; 30: 4493–4500.

Off-label versus on-label prescribing of oral oncology agents on time to receipt of medication in patients with soft tissue sarcoma

Abstract

Purpose

Patients and methods

Results

Conclusions

Keywords

Get full access to this article

References